BioVaxys reports positive phase 1B/2 ovarian cancer trial results Jan 20, 2026 08:04AM
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Ca Jan 20, 2026 08:00AM
BioVaxys reports positive phase 1 results for bladder cancer vaccines Jan 8, 2026 08:04AM
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer Jan 8, 2026 08:00AM
BioVaxys reports positive phase 1 results for breast cancer treatment Dec 17, 2025 08:03AM


Dec 17, 2025 08:00AM BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
May 7, 2025 09:12AM BioVaxys and Sona Nanotech Enter Research Collaboration